SPDR® S&P Pharmaceuticals ETF (XPH)
39.37
-0.42
(-1.06%)
USD |
NYSEARCA |
Apr 24, 16:00
39.37
0.00 (0.00%)
After-Hours: 19:03
Price Chart
Key Stats
Net Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
---|---|---|---|
0.35% | 0.06% | 192.88M | 38297.50 |
Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (Since Inception) |
1.50% | 53.00% | 15.70M | Upgrade |
Basic Info
Investment Strategy | |
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Mid Cap/Value |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Global Category Name | Healthcare Sector Equity |
YCharts Categorization | Healthcare Equity |
YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | SPDR State Street Global Advisors |
Prospectus Benchmark Index | |
S&P Pharms Select Industry TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Karl Schneider | 9.42 yrs |
Keith Richardson | 7.25 yrs |
Performance Versus Category
As of April 23, 2024. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of April 23, 2024.
Basic Info
Investment Strategy | |
The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the pharmaceuticals segment of a U.S. total market composite index. In seeking to track the performance of the S&P Pharmaceuticals Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the pharmaceuticals segment of the S&P Total Market Index ("S&P TMI"). |
General | |
Security Type | Exchange-Traded Fund |
Equity Style | Mid Cap/Value |
Fixed Income Style | -- |
Broad Asset Class | Sector Equity |
Broad Category | Equity |
Category Name | Health |
Category Index | S&P 1500 Health Care TR |
Global Category Name | Healthcare Sector Equity |
YCharts Categorization | Healthcare Equity |
YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
Prospectus Objective | Specialty - Health |
Fund Owner Firm Name | SPDR State Street Global Advisors |
Prospectus Benchmark Index | |
S&P Pharms Select Industry TR USD | 100.0% |
Broad Asset Class Benchmark Index | |
^MSWNTR | 100.0% |
Manager Tenure | |
Karl Schneider | 9.42 yrs |
Keith Richardson | 7.25 yrs |